Blood Test Predicts Alzheimer’s Progression in Cognitively Healthy Older Adults
Research shows the pTau217 biomarker can identify risk for cognitive decline and amyloid buildup before changes appear on brain scans.
Category: Dementias & Alzheimer’s
Dementias & Alzheimer’s
Latest
Dementias & Alzheimer’s
Latest
Roche Receives CE Mark for Blood-Based Immunoassay Test to Detect Alzheimer’s Genetic Risk Factor ApoE4
The test identifies carriers of a genetic variant found in up to 60% of Alzheimer's patients, helping clinicians triage patients and guide treatment decisions.
Dementias & Alzheimer’s
Latest
Study Links Fat Transport Molecules to Alzheimer’s Risk Based on Genetics
Research finds lysophosphatidylcholines either promote or protect against disease depending on APOE ε4 gene status, with implications for personalized treatments.
Digital Cognitive Test Helps Identify Primary Care Patients Who Need Alzheimer’s Blood Biomarker Testing
Researchers say the digital assessment improves early identification of patients likely to benefit from blood biomarker testing for Alzheimer’s disease.
Read More
Lab Validates FDA-Cleared Blood-Based Alzheimer’s Biomarker Assay Under EU Regulations
The validation enables its use as a blood-based biomarker for inclusion and exclusion in clinical trials in both the United States and Europe.
Read More
New FDA-Cleared Blood Test Moves Alzheimer’s Assessment into Primary Care
Roche’s Elecsys pTau181 assay gives clinical labs a key role in the initial evaluation of cognitive decline, helping to rule out amyloid pathology earlier in the diagnostic process.
Read More
Study Demonstrates Accuracy of Two Quest Blood Tests for Alzheimer’s Diagnosis
Two biomarker panels demonstrated 91% sensitivity and specificity in symptomatic patients, potentially reducing the need for PET imaging confirmation.
Read More
Labcorp to Offer FDA-Cleared Blood Test for Alzheimer’s Assessment in Primary Care
The Elecsys pTau181 test measures phosphorylated Tau 181 protein to help rule out Alzheimer’s-related amyloid pathology in patients 55 and older.
Read More
FDA Clears Blood Test for Alzheimer’s Assessment in Primary Care
The test measures phosphorylated Tau 181 protein to help rule out Alzheimer’s-related amyloid pathology in patients 55 and older.
Read More
New Blood-Based Assay Targets Brain-Specific Alzheimer’s Biomarker
The single-plex assay, for research use only, measures brain-derived phosphorylated tau 217 from plasma, serum, and dried blood spots without requiring cerebrospinal fluid collection.
Read More
C2N Diagnostics Lowers Age Limit for Alzheimer’s Blood Test to 50
C2N Diagnostics has expanded the intended use of its PrecivityAD2 Alzheimer’s disease blood test to include patients 50 years and older, lowering the previous age limit from 60 years.
Read More
How a New Blood Test and Research Are Aimed at Diagnosing and Preventing Alzheimer’s Disease
A Rutgers research director outlines clinical applications and limitations of the new diagnostic tool while highlighting the need for specialist interpretation.
Read More
First FDA-Cleared Blood Test for Alzheimer’s Disease Launches
The test offers a less invasive alternative to cerebrospinal fluid testing and PET scans for detecting amyloid plaques.
Read More
Korean Researchers Develop SERS Platform 100,000 Times More Sensitive Than ELISA for Alzheimer’s Detection
The surface-enhanced Raman spectroscopy platform can detect amyloid beta biomarkers at ultra-low concentrations in body fluids, potentially enabling earlier diagnosis and monitoring of disease progression.
Read More
pTau217 Antibody Demonstrates Reliability for Alzheimer’s Detection
ALZpath pTau217 antibody data was included in 37 submissions at AAIC, building on research demonstrating its sensitivity and accuracy in blood-based tests for Alzheimer’s disease.
Read More
Blood-Based Biomarker Testing for Alzheimer’s Gets Formal Guidance
The Alzheimer’s Association released its first clinical practice guideline on the use of blood-based biomarker tests.
Read More
AI-Enhanced EEG Promises Early Alzheimer’s Detection
AI-enhanced EEG technology is emerging as a promising tool for early detection of Alzheimer’s disease, potentially facilitating prevention efforts before symptoms appear.
Read More
Roche Shares Alzheimer’s Drug and Diagnostic Advances at AAIC 2025
At the Alzheimer’s Association International Conference, Roche shared new data on its investigational antibody trontinemab and its Elecsys pTau217 blood test.
Read More